Allogene Therapeutics, Inc. (ALLO)
2.165
-0.12
(-5.04%)
USD |
NASDAQ |
Apr 15, 16:00
2.14
-0.02
(-1.15%)
After-Hours: 20:00
Allogene Therapeutics Research and Development Expense (Annual) : 137.79M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ANI Pharmaceuticals, Inc. | 51.66M |
| Inovio Pharmaceuticals, Inc. | 52.79M |
| Vaxart, Inc. | 201.58M |
| Capricor Therapeutics, Inc. | 83.50M |
| Agenus, Inc. | 79.34M |